In its latest quarterly filing, Outlook Therapeutics disclosed early-stage commercialization of its first ophthalmic bevacizumab formulation approved in the EU and UK for wet AMD, with launches in Germany and the UK starting mid-2025. The company continues to pursue FDA approval amid multiple complete response letters requiring further clinical and manufacturing data. Financially, Outlook maintains a cash balance of approximately $7.7 million as of March 2026 and has entered a new $100 million ATM equity offering to support operations. The company’s competitive edge is anchored on regulatory approvals that provide an alternative to off-label bevacizumab use, but significant risks remain from regulatory uncertainties, competitive pressures, and capital constraints.